Ultragenyx Pharma(RARE.US)

Event Tracking

Dec30

Ultragenyx Completes Rolling Submission of BLA for DTX401 Gene Therapy

21:12

Dec29

William Blair Analyst Maintains Buy Rating on Ultragenyx

16:42

Ultragenyx Announces Setriusumab Phase 3 Trial Misses Main Endpoint

13:30

Dec11

Ultragenyx CFO Reports Sale of Company Shares

17:12

Nov16

Ultragenyx Secures $400 Million Non-Dilutive Financing and Expands Crysvita Royalties

22:02

Nov5

Morgan Stanley Reiterates Buy Rating on Ultragenyx Pharmaceutical

17:21

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 159.93 M, Net Income -180.41 M, EPS -1.8082

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 166.5 M, Net Income -114.95 M, EPS -1.1674

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 139.29 M, Net Income -151.08 M, EPS -1.569

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change